Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Position Boosted by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 10.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,335 shares of the company’s stock after acquiring an additional 2,854 shares during the period. JPMorgan Chase & Co. owned approximately 0.07% of Y-mAbs Therapeutics worth $399,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Principal Financial Group Inc. bought a new stake in shares of Y-mAbs Therapeutics during the third quarter valued at about $267,000. Barclays PLC increased its stake in Y-mAbs Therapeutics by 433.4% during the 3rd quarter. Barclays PLC now owns 69,222 shares of the company’s stock valued at $910,000 after buying an additional 56,244 shares during the period. Empire Financial Management Company LLC bought a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter worth about $210,000. Geode Capital Management LLC lifted its stake in shares of Y-mAbs Therapeutics by 6.2% in the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after acquiring an additional 47,846 shares during the period. Finally, State Street Corp boosted its holdings in shares of Y-mAbs Therapeutics by 50.4% in the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after acquiring an additional 405,169 shares in the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Oppenheimer initiated coverage on Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price for the company. Wedbush restated an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Finally, Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $20.89.

Y-mAbs Therapeutics Trading Up 1.0 %

NASDAQ YMAB opened at $6.15 on Thursday. Y-mAbs Therapeutics, Inc. has a 1 year low of $5.93 and a 1 year high of $20.90. The company has a market cap of $275.45 million, a PE ratio of -11.39 and a beta of 0.69. The stock’s 50-day moving average price is $8.48 and its two-hundred day moving average price is $11.63.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The firm had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. During the same quarter in the prior year, the firm earned ($0.18) EPS. Research analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.64 EPS for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.